All Updates

All Updates

icon
Filter
Partnerships
AbSci and Merck collaborate on USD 610 million AI deal
AI Drug Discovery
Jan 7, 2022
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Product updates
Partnerships
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
AI Drug Discovery

AI Drug Discovery

Jan 7, 2022

AbSci and Merck collaborate on USD 610 million AI deal

Partnerships

  • Washington-based synthetic biology platform AbSci has entered into a USD 610 million research collaboration with Merck (known as MSD outside the United States and Canada) to discover and develop novel therapeutics across undisclosed therapeutic areas.

  • The duo will research three targets by leveraging AbSci’s synthetic biology and AI-powered integrated drug creation platform; Merck has the option to progress the targets by entering into a drug discovery collaboration agreement afterward. The partnership will also leverage AbSci’s non-standard amino acid technology to develop enzymes specific to Merck’s biomanufacturing applications.

  • AbSci will receive a total of USD 610 million consisting of an upfront payment, milestone payments, tiered royalties on sales, and research funding. A breakdown of how the payments will be received was not disclosed.

  • Analyst QuickTake: Merck and AbSci have already been involved since February 2021 via a strategic investment of around USD 5 million from the Merck Global Health Innovation Fund (Merck GHI) to support the development of AbSci’s deep learning platform Denovium Engine. The company’s share price hiked by 17% with the latest collaboration, indicating an increase in investor confidence, partially recovering its slumped share price since its IPO in July 2021 .

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.